Abstract: Disclosed herein are systems and methods for immunity data creation and immunity monitoring (e.g., management, maintenance, etc.). A user may upload immunity and redaction data. A community of other users may verify the uploaded data. A venue may comprise a target immunity level and an actual immunity level. Combining the verified uploaded data with the actual immunity level may yield a new actual immunity level. The user may be allowed to enter the venue if the new actual immunity level is at or above the target immunity level.

Abstract: Disclosed herein are systems and methods for immunity data creation and immunity monitoring (e.g., management, maintenance, etc.). A user may upload immunity and redaction data. A community of other users may verify the uploaded data. A venue may comprise a target immunity level and an actual immunity level. Combining the verified uploaded data with the actual immunity level may yield a new actual immunity level. The user may be allowed to enter the venue if the new actual immunity level is at or above the target immunity level.

Abstract: The present invention is a method of treating antifolate neurotoxicity in a mammal suffering from or at risk of developing antifolate neurotoxicity, which comprises administering to the mammal a therapeutically effective amount of an NMDA antagonist, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.

Abstract: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.